The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...

Dublin, Aug. 26, 2020 (GLOBE NEWSWIRE) -- The "Global Implantable Loop Recorders Market By Application (Atrial fibrillation, Cardiac Arrhythmia and Cardiac syncope), By End User (Hospitals, Cardiac ...

Wilmington, Delaware, United States, June 12, 2023 (GLOBE NEWSWIRE) -- The global cardiac implantable electronic devices market was valued at USD 10.8 Bn in 2021 and is projected to reach more than ...

Using an implantable loop recorder (ILR) to screen older individuals for atrial fibrillation (AF) may be more beneficial when NT-proBNP levels are high, according to a post hoc analysis of the LOOP ...

Experts note that implantable loop recorders are valuable for detecting infrequent arrhythmias and guiding anticoagulation decisions post-cryptogenic stroke or atrial fibrillation ablation, but due to ...

Doctors at Columbus Community Hospital now have a high-tech new tool that can help them diagnose irregular heart rhythms that may not show up during standard testing. The tool, called a cardiac loop ...

Background: A relaxation of the prohibition of scanning cardiac rhythm device patients is underway, largely because of the growing experience of safe scanning events at 1.5T. Magnetic resonance ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.